Background and objective Pimecrolimus cream 1% is an effective treatment for atopic eczema. The aim was to investigate its efficacy in asteatotic eczema, a skin disease similar to atopic eczema and its associated dry skin and itching.
Methods Single-centre, randomized, double-blind, vehicle controlled study in 40 patients with asteatotic eczema. Efficacy was assessed by eczema area and severity index (EASI), investigators global assessment (IGA), patient's self-assessment, and pruritus severity.
Results After 4 weeks of treatment, EASI, the primary efficacy variable, was reduced by 62 ± 7% from baseline in patients on pimecrolimus, compared to 21 ± 14% in patients on vehicle (P = 0.013). With pimecrolimus there was also a better control of pruritus (P = 0.042) at week 4 whereas a better control of disease according to self-assessment could only be observed at weeks 2 (P = 0.01) and week 3 (P = 0.08).
Conclusion Pimecrolimus cream 1% is effective in patients with asteatotic eczema.